Red blood cells membrane vehicle co-delivering DOX and IR780 for effective prostate cancer therapy
Source abstract
Abstract
The cellular accumulation of drug delivery systems (DDSs) is a critical parameter to determine the final outcome of cancer chemotherapy. Herein, we designed a red blood cells membrane-based vehicle (RV) and employed it to load both doxorubicin (Dox) and IR 780 (RV/I-D). The photothermal-assisted chemotherapy efficacy of RV/I-D on the treatment of cancer was tested on a prostate cancer model. Excitingly, the results showed that RV/I-D was stable and safe nanoparticles with size at about 100 nm. Moreover, upon the increase of system temperature using photothermal effects of IR780, the drug release of the DDS was accelerated. Above all, the DDS also increased the accumulation of drugs into the Dox-resistant prostate cancer cells (PC-3/Dox) bothin vitroandin vivoand showed enhanced anticancer performance.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Erythrocyte Function and Pathophysiology · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. 10.1039/C7NR07810B10.1039/C7NR07810B ↗
2. 10.1002/adhm.20190050110.1002/adhm.201900501 ↗
3. 10.1016/j.actbio.2018.12.02010.1016/j.actbio.2018.12.020 ↗
4. 10.1016/j.biopha.2020.11037110.1016/j.biopha.2020.110371 ↗
5. 10.1080/21691401.2019.162255410.1080/21691401.2019.1622554 ↗
6. 10.1016/j.colsurfb.2017.05.01210.1016/j.colsurfb.2017.05.012 ↗
7. Tumor-draining lymph node targeting chitosan micelles as antigen-capturing adjuvants for personalized immunotherapy10.1016/j.carbpol.2020.116270 ↗
8. 10.7150/thno.2298910.7150/thno.22989 ↗
9. 10.1016/j.ijpharm.2018.11.05610.1016/j.ijpharm.2018.11.056 ↗
10. 10.1039/D0NR00039F10.1039/D0NR00039F ↗
11. 10.1039/C9NR09131A10.1039/C9NR09131A ↗
12. 10.1016/j.carbpol.2017.10.03310.1016/j.carbpol.2017.10.033 ↗
13. 10.1002/adma.20170640710.1002/adma.201706407 ↗
14. 10.1016/j.jconrel.2017.09.04210.1016/j.jconrel.2017.09.042 ↗
15. 10.1002/jcb.2650210.1002/jcb.26502 ↗
16. 10.1021/acsnano.8b0563910.1021/acsnano.8b05639 ↗
17. 10.1038/nprot.2014.01610.1038/nprot.2014.016 ↗
18. Near infrared photothermal-responsive poly (vinyl alcohol)/black phosphorus composite hydrogels with excellent on-demand drug release capacity10.1039/C7TB03090H ↗
19. 10.7150/thno.3793010.7150/thno.37930 ↗
20. 10.2147/IJN.S14046210.2147/IJN.S140462 ↗
21. 10.7150/thno.2778710.7150/thno.27787 ↗
22. 10.1016/j.colsurfb.2018.11.08810.1016/j.colsurfb.2018.11.088 ↗
23. 10.1016/j.colsurfb.2018.06.01710.1016/j.colsurfb.2018.06.017 ↗
24. 10.2147/IJN.S23715610.2147/IJN.S237156 ↗
25. 10.2147/IJN.S19397610.2147/IJN.S193976 ↗
26. 10.1002/jcb.2652710.1002/jcb.26527 ↗
27. 10.1039/C7MH00991G10.1039/C7MH00991G ↗
28. 10.1039/D0NR02291H10.1039/D0NR02291H ↗
29. 10.1080/1061186X.2018.149703910.1080/1061186X.2018.1497039 ↗
30. 10.1080/10717544.2018.156440310.1080/10717544.2018.1564403 ↗
31. 10.7150/thno.2759810.7150/thno.27598 ↗
32. 10.1016/j.jddst.2019.10136910.1016/j.jddst.2019.101369 ↗
33. 10.1039/C7NR09196F10.1039/C7NR09196F ↗
34. 10.2147/IJN.S20291010.2147/IJN.S202910 ↗
35. 10.2147/IJN.S20310810.2147/IJN.S203108 ↗
36. 10.1002/adhm.20170139410.1002/adhm.201701394 ↗
37. 10.1016/j.carbpol.2019.03.03310.1016/j.carbpol.2019.03.033 ↗
38. 10.1166/jbn.2017.235610.1166/jbn.2017.2356 ↗
39. 10.1039/C8NR05323E10.1039/C8NR05323E ↗
40. 10.1016/j.colsurfb.2019.02.00110.1016/j.colsurfb.2019.02.001 ↗
41. 10.1002/adhm.20180048510.1002/adhm.201800485 ↗